ESOPHAGEAL ADENOCARCINOMA (EAC)
Clinical trials for ESOPHAGEAL ADENOCARCINOMA (EAC) explained in plain language.
Never miss a new study
Get alerted when new ESOPHAGEAL ADENOCARCINOMA (EAC) trials appear
Sign up with your email to follow new studies for ESOPHAGEAL ADENOCARCINOMA (EAC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy combo aims to extend lives in esophageal cancer
Disease control OngoingThis phase 3 trial tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemoradiotherapy helps people with esophageal cancer live longer and delay recurrence. About 700 participants who cannot have surgery will receive either pembrolizumab or a placeb…
Matched conditions: ESOPHAGEAL ADENOCARCINOMA (EAC)
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
French study tracks Real-World success of combo therapy for stomach cancer
Knowledge-focused OngoingThis study observes 208 adults in France with advanced or metastatic stomach, esophageal, or gastroesophageal junction cancer who are receiving nivolumab combined with chemotherapy as their first treatment. Researchers will track how long patients live and how their disease progr…
Matched conditions: ESOPHAGEAL ADENOCARCINOMA (EAC)
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC